MYUNGMOON PHARM CO.,LTD Logo

MYUNGMOON PHARM CO.,LTD

Develops, manufactures, and commercializes prescription & OTC medicines for global markets.

017180 | KO

Overview

Corporate Details

ISIN(s):
KR7017180001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 제약공단2길 26, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Myungmoon Pharm. Co., Ltd., established in 1983, is a research-based pharmaceutical company engaged in the development, manufacturing, and commercialization of healthcare products. The company's portfolio includes a range of ethical (ETC) prescription drugs and over-the-counter (OTC) medicines. It operates through the entire pharmaceutical value chain, from research and development to the import, export, and distribution of its products. Myungmoon Pharm serves both the domestic South Korean market and international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.7 KB
2025-03-26 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-14 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 206.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 222.5 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 203.2 KB
2025-02-19 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 14.1 KB
2025-01-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 21.4 KB
2025-01-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 25.7 KB
2024-11-20 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 3.9 KB

Automate Your Workflow. Get a real-time feed of all MYUNGMOON PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MYUNGMOON PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MYUNGMOON PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America
AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America
AMGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.